ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023
Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 77 citations in OpenAlex.
- Daratumumab plus bortezomib and dexamethasone (Dara-VD) in newly diagnosed Mayo 2004 stage IIIA and IIIB light-chain amyloidosis: Long-term follow-up results from a prospective phase 2 study.British journal of haematology · 2026Trial
- Improved survival with daratumumab-CyBorD compared with CyBorD as frontline therapy for AL amyloidosis.Blood neoplasia · 2025Trial
- Efficacy and safety of daratumumab plus bortezomib and dexamethasone in newly diagnosed Mayo 2004 stage IIIA or IIIB light-chain amyloidosis: a prospective phase II study.Haematologica · 2024Trial
- Trial
- Daratumumab monotherapy for relapsed AL amyloidosis: a single center retrospective analysis.Blood research · 2026Article
- A Multicenter National Study of AL Amyloidosis in China: Insights Into Real-World Diagnosis, Treatment, and Prognosis.American journal of hematology · 2026Article
- Long-Term Outcomes of Mayo Stage IIIb AL Amyloidosis Treated With Daratumumab-Based Frontline Therapy.American journal of hematology · 2026Article
- A Clinically Applicable Conversion Formula Between NT-proBNP and BNP in Light-Chain Amyloidosis.JACC. CardioOncology · 2026Article
- Management of relapsed/refractory AL amyloidosis.Blood advances · 2026Review
- Article
- Teclistamab in relapsed/refractory light chain amyloidosis: A retrospective multicenter study by the German Society for Amyloid Diseases.HemaSphere · 2026Article
- Cardiac Biomarker Complete Response in Light Chain Amyloidosis: How Much of the Heart Is Captured?JACC. CardioOncology · 2026Article
- Cardiac Biomarker Complete Response in AL Amyloidosis: Characteristics, Cardiac Recovery, and Survival of 63 Patients.JACC. CardioOncology · 2026Article
- Talquetamab induces deep responses in heavily pre-treated patients with systemic light-chain amyloidosis.Annals of hematology · 2026Article
- Long-term outcomes of autologous stem cell transplantation for AL amyloidosis: a 15-year experience from a Chinese referral center and a comparison of different eras.Blood cancer journal · 2026Article
- Hepatic Response Dynamics in Newly Diagnosed Patients with Light-chain Amyloidosis: A Retrospective Cohort Study.Advances in therapy · 2026Article
- Echocardiographic Markers of Cardiac Response to Therapy in Patients with Light Chain Amyloidosis.Echocardiography (Mount Kisco, N.Y.) · 2026Article
- Eligibility criteria for clinical trials in AL amyloidosis result in exclusion of nearly half of real-world patients.HemaSphere · 2026Article
- Biopsy-resolved cryo-EM structures of amyloid fibrils provide molecular insights into AL amyloidosis.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Unveiling the unseen: navigating heart involvement in amyloidosis with biomarkers beyond the horizons of imaging.European heart journal. Imaging methods and practice · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 11 institutions in 6 countries.
Funding
Abstract
purposeBinary cardiac response assessment using cardiac biomarkers is prognostic in light chain amyloidosis. Previous studies suggested four-level cardiac responses using N-terminal prohormone of brain natiuretic peptide improves prognostic prediction. This study was designed to validate graded cardiac response criteria using N-terminal prohormone of brain natiuretic peptide/brain natiuretic peptide. PATIENTS AND
methodsThis retrospective, multicenter study included patients with light chain amyloidosis who achieved at least a hematologic partial response (PR) and were evaluable for cardiac response. Four response criteria were tested on the basis of natriuretic peptide response depth: cardiac complete response (CarCR), cardiac very good partial response (CarVGPR), cardiac PR (CarPR), and cardiac no response (CarNR). Response was classified as best response and at fixed time points (6, 12, and 24 months from therapy initiation). The study primary outcome was overall survival.
results651 patients were included. Best CarCR, CarVGPR, CarPR, and CarNR were achieved in 16%, 26.4%, 22.9%, and 34.7% of patients, respectively. Patients in cardiac stage II were more likely to achieve CarCR than patients in cardiac stage IIIA and IIIB (22%
conclusionGraded cardiac response criteria allow better assessment of cardiac improvement compared with the traditional binary response system. The study re-emphasizes the importance of early diagnosis, which increases the likelihood of deep cardiac responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.